Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2003 1
2005 2
2006 1
2008 1
2009 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Henderson ST, et al. Among authors: barr lj. Nutr Metab (Lond). 2009 Aug 10;6:31. doi: 10.1186/1743-7075-6-31. Nutr Metab (Lond). 2009. PMID: 19664276 Free PMC article.
Hypometabolism as a therapeutic target in Alzheimer's disease.
Costantini LC, Barr LJ, Vogel JL, Henderson ST. Costantini LC, et al. Among authors: barr lj. BMC Neurosci. 2008 Dec 3;9 Suppl 2(Suppl 2):S16. doi: 10.1186/1471-2202-9-S2-S16. BMC Neurosci. 2008. PMID: 19090989 Free PMC article. Review.
Epidermal DNA vaccine for influenza is immunogenic in humans.
Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Drape RJ, et al. Among authors: barr lj. Vaccine. 2006 May 22;24(21):4475-81. doi: 10.1016/j.vaccine.2005.08.012. Epub 2005 Aug 19. Vaccine. 2006. PMID: 16150518 Clinical Trial.
Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.
Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Rottinghaus ST, et al. Among authors: barr lj. Vaccine. 2003 Nov 7;21(31):4604-8. doi: 10.1016/s0264-410x(03)00447-x. Vaccine. 2003. PMID: 14575774 Clinical Trial.
Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device.
Roberts LK, Barr LJ, Fuller DH, McMahon CW, Leese PT, Jones S. Roberts LK, et al. Among authors: barr lj. Vaccine. 2005 Sep 23;23(40):4867-78. doi: 10.1016/j.vaccine.2005.05.026. Vaccine. 2005. PMID: 15985318 Clinical Trial.
Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine.
Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, Vessey R, King A, Ogg G, Gallimore A, Haynes JR, Heydenburg Fuller D. Roy MJ, et al. Among authors: barr lj. Vaccine. 2000 Nov 22;19(7-8):764-78. doi: 10.1016/s0264-410x(00)00302-9. Vaccine. 2000. PMID: 11115698 Clinical Trial.
Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B.
Swain WE, Heydenburg Fuller D, Wu MS, Barr LJ, Fuller JT, Culp J, Burkholder J, Dixon RM, Widera G, Vessey R, Roy MJ. Swain WE, et al. Among authors: barr lj. Dev Biol (Basel). 2000;104:115-9. Dev Biol (Basel). 2000. PMID: 11713809 Clinical Trial.
Feedback